Pfizer has released the results of one of the four vaccines against Sars-CoV-2 that is being developed in partnership with the biotechnology company BioNTech.
The pharmaceutical company Pfizer announced the success of the initial tests carried out with one of the four candidates for the vaccine against Sars-CoV-2 that the company is developing in partnership with BioNTech. The initial results of the program, called BNT162, were shared in the preprint server MedRxiv.
According to the scientists, each of the four vaccines being tested has a messenger RNA that carries the virus’s genetic material and has a target particle. The vaccines focus on one of the crucial receptors for the functioning of Sars-CoV-2, the receptor-binding domain (RBD).
“These preliminary data are encouraging in that they provide an initial signal that BNT162b1 targeting the RBD SARS-CoV-2 is able to produce neutralizing antibody responses in humans at or above the levels observed in convalescent sera,” said Ugur Sahin, one of the researchers, in a statement. “We look forward to providing further data updates on BNT162b1.”
The initial part of the study included 45 healthy adults, aged 18 to 55 years. 24 received two injections, one of 10 µg and the other 30 µg of the vaccine; while 12 received a single injection of 100 µg and 9 subjects received 2 placebo doses.
Although they had mild side effects, the best results were seen in the group that received both doses of the vaccine, but everyone who received the drug developed antibodies to the new coronavirus. Scientists now plan to start a new phase of testing with the formula, the goal is to evaluate its effectiveness in a group of 30,000 people.
“We are dedicated to develop potentially groundbreaking vaccines and medicines, and in the face of this global health crisis, we approach this goal with the utmost urgency,” said Kathrin Jansen, who also participated in the research. “We look forward to publishing our clinical data in a peer-reviewed journal as quickly as possible.”